Bumper Listing Alert: Influx Healthtech IPO Debuts with 38% Premium on NSE SME, Surpasses GMP Expectations

Mumbai-based healthcare manufacturer Influx Healthtech made a stellar debut on the NSE Emerge platform on June 25, 2025, with its shares listing at ₹132.50 apiece-a sharp 38% premium over the IPO issue price of ₹96. This bumper listing surpassed expectations from the grey market, which had projected a more modest 21% listing gain, with GMP suggesting a price of around Rs.116.

The Influx Healthtech IPO has officially become one of the most talked-about issues of the year, clocking a staggering 201.35 times total subscription by the close of Day 3 on June 20, 2025. The overwhelming demand crushed earlier expectations and prepared investors for a blockbuster debut on the NSE Emerge platform.

Take a Poll

Investor enthusiasm was clearly off the charts, with non-institutional investors (NIIs) driving the frenzy by subscribing to a jaw-dropping 481.10 times their allotted quota. Meanwhile, Qualified Institutional Buyers (QIBs) showed surprisingly aggressive interest as well, with their segment getting subscribed to 137.87 times. Retail individual investors are bidding 117.68 times.

With a total issue size of Rs.55.63 crore, including a fresh issue of Rs. 45.07 crore and an offer for sale of Rs. 10.56 crore, the IPO price band was set between Rs. 91 and Rs. 96 per share. The company had already raised Rs. 16.67 crore from anchor investors on June 17, adding early credibility to the offer.

IPO Details: Price Band, Lot Size, and Investment Requirements

The Influx Healthtech IPO, open from June 18 to June 20, comprises a fresh issue of Rs. 45.07 crore and an offer for sale (OFS) of Rs. 10.56 crore. The IPO price band was fixed between Rs. 91 and Rs. 96 per share, with a face value of Rs. 10. Influx Healthtech IPO raises Rs. 16.67 crore from anchor investors. Influx Healthtech IPO anchor bid date is June 17, 2025.

Grey Market Premium

This listing performance exceeded the final grey market premium (GMP) of Rs. 20, which had suggested a more modest 20.83% expected gain. The IPO allotment was finalised on Monday, June 23, 2025, and the shares listed today on the NSE SME exchange.

About Influx Healthtech

Influx Healthtech, a leading player in the healthcare manufacturing sector, operates certified facilities with GMP, HACCP, ISO 22000, and Halal accreditations. Founded in September 2020, the company specialises in contract development and manufacturing (CDMO) services. The company offers end-to-end solutions across various industries, catering to both domestic and international clients. The company operates three fully equipped manufacturing facilities located in Thane, Maharashtra, spanning 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft., respectively. These facilities are designed to meet stringent industry standards, enabling the company to deliver high-quality and scalable production services across pharmaceuticals, nutraceuticals, and wellness products.

Disclaimer: The information provided in this article is for general informational purposes only and does not constitute financial, investment, or credit advice. The views and recommendations mentioned are based on publicly available data and expert opinions at the time of writing. Neither the author nor GoodReturns endorses any specific product or financial decision. GoodReturns.in and its affiliates are not responsible for any loss or damage resulting from reliance on the information presented.